![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
SOUTH SAN FRANCISCO, Calif., March 10, 2011 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSSD) today announced that the European Patent Office (EPO) has granted European Patent No...
SOUTH SAN FRANCISCO, Calif., March 9, 2011 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSSD) a biopharmaceutical company focused on the development and commercialization of new...
SOUTH SAN FRANCISCO, Calif., March 3, 2011 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSSD) today announced that it has received notification from The NASDAQ Stock Market that it...
SOUTH SAN FRANCISCO, Calif., March 1, 2011 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSSD), a biopharmaceutical company focused on the development and commercialization of new...
NEW YORK, NY -- (Marketwire) -- 02/24/11 -- There is plenty of optimism surrounding the Biotech industry as firmer pricing and new products have improved sales and earnings trends. Meanwhile...
SOUTH SAN FRANCISCO, Calif., Feb. 24, 2011 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSSD) a biopharmaceutical company focused on the development and commercialization of new...
SOUTH SAN FRANCISCO, Calif., Feb. 23, 2011 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSSD) today announced that vosaroxin, the Company's lead drug candidate, has been granted...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions